The efficacy of ramucirumab plus paclitaxel (n = 330) versus placebo plus paclitaxel (n = 335) was assessed in previously treated patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. The RAINBOW double-blind randomized phase III clinical trial reported a higher incidence of adverse events in patients on ramucirumab than in those receiving placebo. However, overall survival was significantly longer in the ramucirumab than the placebo group (median 9.6 versus 7.4 months, respectively; P = 0.017).
References
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction carcinoma (RAINBOW): a double-blind randomised phase 3 trial. Lancet Oncol. 10.1016/S1470-2045(14)70420-6
Rights and permissions
About this article
Cite this article
Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer. Nat Rev Gastroenterol Hepatol 11, 642 (2014). https://doi.org/10.1038/nrgastro.2014.174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.174